email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2056 - 2070
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Shandong Fontacea In-Licenses IL-17A Candidate from Janssen
$5.00
Available
KeChow Completes $45 Million Round for Novel Cancer Drug Development
$5.00
Available
FC Capital of Shanghai Leads $20 Million B Round for Switzerland's Cellestia Biotech
$5.00
Available
TransThera Approved for US Trials of Heart Failure Treatment
$5.00
Available
Ally Bridge Leads $140 Million of Investments in Three Medical Device Companies
$5.00
Available
BeiGene Says BTK Inhibitor Shows Improvement But Does not Meet Clinical Endpoints in WM
$5.00
Available
3SBio Has China Rights to Five Numab I-O Therapies following $15.2 Million Investment
$5.00
Available
AstraZeneca's Imfinzi, a PD-L1 Immunotherapy, Approved in China for NSCLC
$5.00
Available
Alphamab Oncology Closes $234 Million Hong Kong IPO; Climbs 35% in First Session
$5.00
Available
Zhejiang Medicine Reports Positive Data for HER2 Treatment in Pretreated Patients
$5.00
Available
Ascentage Reports 95% Complete Response of BCR-ABL Inhibitor in Leukemia Patients
$5.00
Available
JOINN Bio Raises $60 Million for US-China Biologic CDMO Operations
$5.00
Available
Innovent Announces 100% Response Rate for its CAR-T in Multiple Myeloma
$5.00
Available
BJ Bio Starts US Trials of Targeted IL-15 Fusion Protein in Solid Tumors
$5.00
Available
BeiGene Reports More Clinical Data on BTK-inhibitor Brukinsa
$5.00
Available